RECAİ TUNCA, Alparslan Kadir DEVRİM, Mahmut SÖZMEN, SERPİL DAĞ, Örsan GÜNGÖR, Emrah İPEK

The Effects of gemfibrozil and ovariectomy on the peroxisome proliferator activated receptors (PPARs) in mice with experimentally induced obesity

Ovarioektomi uygulanan farelerde deneysel olarak oluşturulan obezitenin peroksizom proliferatörleri ile aktive olan reseptörler (PPARs) üzerine etkisi araştırılmıştır. Bu amaçla ovarioektomi ve sham uygulanan fareler yağlı diyet ve düşük yağlı diyetle 15 hafta süre ile beslendi. Ayrıca, ovarioektomi ve sham uygulanan farelere farklı diyetlerle beraber 100 mg/kg dozunda oral gemfibrozil uygulandı. Çalışma sonunda ovarioektomi operasyonu uygulanan farelerde sham uygulanan farelere göre istatistiksel olarak anlamlı (P

Deneysel obezite oluşturulan farelerde ovarioektomi operasyonu ve gemfibrozilin peroksizom proliferatörleri ile aktive olan reseptörler (PPARs) ve obezite üzerine etkilerinin araştırılması

Effects of gemfibrozil and ovariectomy on Peroxisome Proliferator Activated Receptors (PPARs) activity were studied in obese mice. Ovariectomised and sham operated mice were fed with high fat diet and low fat diet for 15 weeks. Furthermore, gemfibrozil (100 mg/kg) was orally with high fat and low fat diets to the ovariectomised and sham operated mice. Body weights significantly increased in ovariectomised mice compared to sham operated mice (P<0.001) while gemfibrozil supplementation prevented such increase. Steatosis was as well more pronounced in the livers of ovariectomised mice fed with high fat diet compared to sham operated mice. However, liver steatosis was not seen in gemfibrozil supplemented high fat diet fed mice. On the other hand gemfibrozil supplementation slightly increased the liver weights. High fat diet significantly increased liver AST and ALT enzyme levels and serum total cholesterol, triglyceride and VLDL levels while gemfibrozil lowered these parameters. Immunohistochemically, while tissue PPAR-α and PPAR-γ expressions were affected by ovariectomy, diet and gemfibrozil, PPAR-β expression unchanged. While high fat diet incremented liver PPAR-α and PPAR-γ expressions their levels were reduced following ovariectomy operation. Only high fat diet and only gemfibrozil application increased PPAR-α expression level. PPAR-α expression levels were higher in gemfibrozil and high fat diet combined groups compared to all other groups. In conclusion, gemfibrozil reduced abdominal and hepatic fat deposition in mice with high fat diet and ovariectomy.

PDF

___

1. Berger J, Moler DE: Peroxisome proliferator-activated receptors (PPARs): From metabolic control to epidermal wound healing. Swiss Med Wkly, 132, 83-91, 2002.
2. Daynes RA, Jones DJ: Emerging roles of PPARs inflammation and immunity. Nat Rev Med, 53, 748-759, 2002.
3. Jeffrey MP, Susanna STL, Wen L, Jerrold MW, Oksana G, Carrie E, Marc LR, Lynn DH, Frank JG: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β. Mol Cel Biol, 20, 5119-5128, 2000.
4. Wolfrum C, Borrmann CM, Börchers T, Spener F: Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptor a- and -γ mediated gene expression via liver fatty acid binding protein: A signaling path to the nucleus. Proc Natl Acad Sci 98, 2323-2328, 2001.
5. Perreault M, Erbe DV, Tobin JF: PPARγ agonism for the treatment of obesity and associated disorders: Challenges and opportunities. PPAR Res, 1-9, 2008, DOI:10.1155/2008/125387.
6. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W: The PPARalpha- leukotiene B4 pathway to inflammation control. Nature, 384, 39-43, 1996.
7. Xin X, Yang S, Kowalski J, Gerritsen ME: Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem, 274, 9116-9121, 1999.
8. Akbıyık F, Cinar K, Demirpence E, Ozsullu T, Tunca R, Haziroglu R, Yurdaydin C, Uzunalimoglu O, Bozkaya H: Ligand-induced expression of peroxisome proliferator-activated receptor a and activation of fatty acid oxidation enzymes in fatty liver. Eur J Clin Invest, 34, 429-435, 2004.
9. Hashimoto T, Fujita T, Usuda N, Cook W, Qi C, Peters JM, Gonzalez FJ, Yeldandi AV, Rao MS, Reddy JK: Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both PPARα and peroxisomal fatty acyl CoA oxidase: Genotype correlation with fatty liver phenotype. J Biol Chem, 274, 19228-19236, 1999.
10. Yoon M: PPARα in obesity: Sex difference and estrogen involvement. PPAR Res, 2010, DOI:10.1155/2010/584296.
11. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta, 1302, 93-109, 1996.
12. Selek Ş, Karapehlivan M, Citil M, Tunca R, Uzlu E, Erdoğan HM: Effects of gemfibrozil and L-carnitine on PON1 activity, oxidative/anti- oxidative parameters and hepatosteatosis in rabbits feed with fat-rich diet. Kafkas Univ Vet Fak Derg, 17, 183-190, 2011.
13. Yoon M, Jeong S, Lee H, Han M, Kang JH, Kim EY, Kim M, Oh GT: Fenofibrate improves lipid metabolism and obesity in ovariectomised LDL receptor-null mice. Biochem Biophys Res Commun, 302, 29-34, 2003.
14. Iverius H, Brunzell JD: Relationship between lipoprotein lipase activity and plasma sex steroid level in obese women. J Clin Invest, 82, 1106-1112, 1988.
15. Tchernof A, Calles-Escandon J, Sites CK, Poehlman ET: Menopause, central body fatness, and insulin resistance: Effects of hormone-replacement therapy. Coron Artery Dis, 9, 503-511, 1998.
16. Wade GN, Gray JM: Gonadal effects on food intake and adiposity: A metabolic hypothesis. Physiol Behav, 22, 583-593, 1979.
17. Deon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS: Estrogen regulation of adiposity and fuel partitioning: Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem, 280, 35983-35991, 2005.
18. Campbell SE, Mehan KA, Tunstall RJ, Febbraio MA, Cameron-Smith D: 17beta-estradiol upregulates the expression of peroxisome proliferator-activated receptor alpha and lipid oxidative genes in skeletal muscle. J Mol Endocrinol, 31, 37-45, 2003.
19.Djouadi F, Weinheimer CJ, Saffitz J E, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP: A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice. J Clin Invest, 102, 1083-1091, 1998.
20. Wade GN, Gray JM, Bartness TJ: Gonadal influences on adiposity. Int J Obes, 9 (Suppl 1): 83-92, 1985.
21. Asarian L, Geary N: Cyclic estradiol treatment normalizes body weight and restores physiological patterns of spontaneous feeding and sexual receptivity in ovariectomized rats. Horm Behav, 42, 461-471, 2002.
22. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ: Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol, 15, 3012-3022, 1995.
23. Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem, 272, 27307-27312, 1997.
24. Yoon M: The role of PPARα in lipid metabolism and obesity: Focusing on the effects of estrogen on PPARα actions. Pharm Res, 60 (3): 151-159, 2009.
25. Mandard S, Muller M, Kersten S: Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci, 61, 393-416, 2004.
26. Park MK, Han Y, Kim MS, Seo E, Kang S, Park SY, Koh H, Kim DK, Lee HJ: Reduction of food intake by fenofibrate is associated with cholecystokinin release in long-evans Tokushima rats. Korean J Physiol Pharmacol, 16, 181-186, 2012.
27. Homma H, Kurachi H, Nishio Y, Takeda T, Yamamoto T, Adachi K, Morishige K, Ohmichi M, Matsuzawa Y, Murata Y: Estrogen suppresses transcription of lipoprotein lipase gene. Existence of a unique estrogen response element on the lipoprotein lipase promoter. J Biol Chem, 275, 11404-11411, 2000.
28. Lim SC, Caballero AE, Arora S, Smakowski P, Bashoff EM, Brown FM, Logerfo FW, Horton ES, Veves A: The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab, 84, 4159-4164,1999.
29. Waddell TK, Rajkumar C, Cameron JD, Jennings GL, Dart AM, Kingwell BA: Withdrawal of hormonal therapy for 4 weeks decreases arterial compliance in postmenopausal women. J Hypertens, 17, 413-418, 1999.
30. Lehrke M, Lazar MA: The many faces of PPAR-γ. Cell, 123, 993-999, 2005.
31. Gealekman O, Burkart A, Chouinard M, Nicoloro SM, Straubhaar J, Corvera S: Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production. Am J Physiol Endocrinol Metab, 295, E1056-E1064, 2008.
32. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest, 112, 1821-1830, 2003.
33. Ma H, Sprecher HW, Kolattukudy PE: Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPAR- expressing tissue. J Biol Chem, 273, 30131-30138, 1998.
34. Keller H, Givel F, Perroud M, Wahli W: Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol, 9, 794-804, 1995.
35. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor and promotes adipocyte differentiation. Cell, 83, 813-819, 1995.
36. Wilson JL, Huang LS: Temporal response of uterine prostaglandins to estradiol treatment in the ovariectomized-pregnant rat. Prostaglandins, 28, 103-110, 1984.
37. Fayard JM, Chanal S, Felouanti B, Macovski O, Lagarde M, Pageaux JF, Laugier: Regulation of quail oviduct phospholipase A2 activity by estradiol. Eur J Endocrinol, 131, 205-212, 1994.
38. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, Zhou G: Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha. PPAR alpha fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expresson. J Biol Chem, 276(34): 31521-3157, 2001.